Bright Green Corporation Stock

Equities

BGXX

US10920G1004

Pharmaceuticals

End-of-day quote Nasdaq 06:00:00 2024-05-09 pm EDT 5-day change 1st Jan Change
0.2119 USD -4.07% Intraday chart for Bright Green Corporation -1.21% -35.81%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Sales 2022 - Sales 2023 - Capitalization 60.7M
Net income 2022 -27M Net income 2023 -13M EV / Sales 2022 -
Net Debt 2022 3.66 Net Debt 2023 0.19 EV / Sales 2023 -
P/E ratio 2022
-2.75 x
P/E ratio 2023
-4.49 x
Employees 5
Yield 2022 *
-
Yield 2023
-
Free-Float 38.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.07%
1 week-1.21%
Current month-15.54%
1 month-16.57%
3 months+19.04%
6 months-32.86%
Current year-35.81%
More quotes
1 week
0.20
Extreme 0.2005
0.23
1 month
0.16
Extreme 0.1584
0.26
Current year
0.15
Extreme 0.15
0.54
1 year
0.15
Extreme 0.15
1.12
3 years
0.15
Extreme 0.15
58.00
5 years
0.15
Extreme 0.15
58.00
10 years
0.15
Extreme 0.15
58.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 39 22-02-28
47 -
Members of the board TitleAgeSince
Founder 66 19-04-15
Director/Board Member 51 19-12-31
Director/Board Member 57 21-06-30
More insiders
Date Price Change Volume
24-05-10 0.2119 -4.07% 221,982
24-05-09 0.2209 +2.94% 383,818
24-05-08 0.2146 -3.29% 268,432
24-05-07 0.2219 +9.04% 597,083
24-05-06 0.2035 -5.13% 401,565

End-of-day quote Nasdaq, May 09, 2024

More quotes
Bright Green Corporation is a producer and manufacturer of plant-based drugs and active pharmaceutical ingredients (APIs). The Company specializes in the research, production, distribution, and advancement of plant-based drugs and APIs, including psilocybin, psilocyn, peyote, and opium poppy. It plans to focus on the development of cannabis strains and sales of cannabis and hemp products with high contents of cannabinol (CBN) and cannabigerol (CBG). It also plans to cultivate cannabis and focus on the production of dried flowers, and oils and marijuana extracts. In addition to cannabis, It also has a separate area for controlled substance cactus cultivation, and a separate controlled area for mushroom propagation. It is in the process of completing construction of the 22-acre existing greenhouse to comply with the requirements for Schedule I and Schedule II plant-based drugs. It also plans to construct two new 57-acre greenhouses, one each on the Candelaria property and Azuz property.
Related indices
More about the company
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW